HIV-1 Tat-induced microglial activation and neuronal damage is inhibited via CD45 modulation: A potential new treatment target for HAND

American Journal of Translational Research

Volumn 4, Issue 3, 2012, Pages 302-315

  Jin, Jingji ^a   Lam, Lucy ^a   Sadic, Edin ^a   Fernandez, Frank ^a   Tan, Jun ^a,b   Giunta, Brian ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CD45; Dementia; HIV; HIV associated neurocognitive disorders; Microglia

Indexed keywords

CD45 ANTIBODY; CD45 ANTIGEN; INTERLEUKIN 1BETA; LYMPHOCYTE ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; POTASSIUM BISPEROXO(1,10 PHENANTHROLINE)OXOVANADATE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANADIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTOSIS; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE EXACERBATION; ENZYME ACTIVATION; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLAMMATION; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NERVE INJURY; NONHUMAN; PROTEIN FUNCTION;

EID: 84865096921     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. McArthur JC, Steiner J, Sacktor N and Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol 67: 699-714.
2. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V and Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-1799.
3. Dunfee R, Thomas ER, Gorry PR, Wang J, Ancuta P and Gabuzda D. Mechanisms of HIV-1 neurotropism. Curr HIV Res 2006; 4: 267-278.
4. Petito CK, Cho ES, Lemann W, Navia BA and Price RW. Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. J Neuropathol Exp Neurol 1986; 45: 635-646.
5. Ho DD, Rota TR, Schooley RT, Kaplan JC, Allan JD, Groopman JE, Resnick L, Felsenstein D, Andrews CA and Hirsch MS. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985; 313: 1493-1497.
6. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA and Fauci AS. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986; 233: 1089-1093.
7. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR and Ellis RJ. The prevalence and incidence of neurocognitive impairment in the HAART era. Aids 2007; 21: 1915-1921.
8. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B and Epstein L. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8: 136-142.
9. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG and Douek DC. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.
10. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM and Gabuzda D. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008; 3: e2516.
11. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L and Gisslen M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007; 196: 1779-1783.
12. Glass JD, Fedor H, Wesselingh SL and McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995; 38: 755-762.
13. Anthony IC, Ramage SN, Carnie FW, Simmonds P and Bell JE. Influence of HAART on HIVrelated CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005; 64: 529-536.
14. Cross SA, Cook DR, Chi AW, Vance PJ, Kolson LL, Wong BJ, Jordan-Sciutto KL and Kolson DL. Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophagemediated neurotoxicity: a novel candidate for HIV neuroprotection. J Immunol 187: 5015-5025.
15. Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Bales RA, Ethisham A, Greenberg RN and Berger JR. Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol 2004; 10: 223-232.
16. Rumbaugh JA and Nath A. Developments in HIV neuropathogenesis. Curr Pharm Des 2006; 12: 1023-1044.
17. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM and Krammer PH. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375: 497-500.
18. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM and Jeang KT. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A 2000; 97: 11466-11471.
19. Hayashi K, Pu H, Andras IE, Eum SY, Yamauchi A, Hennig B and Toborek M. HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J Cereb Blood Flow Metab 2006; 26: 1052-1065.
20. D'Aversa TG, Yu KO and Berman JW. Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat. J Neurovirol 2004; 10: 86-97.
21. Eugenin EA, Dyer G, Calderon TM and Berman JW. HIV-1 tat protein induces a migratory phenotype in human fetal microglia by a CCL2 (MCP-1)-dependent mechanism: possible role in NeuroAIDS. Glia 2005; 49: 501-510.
22. Hermiston ML, Xu Z and Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003; 21: 107-137.
23. Cosenza-Nashat MA, Kim MO, Zhao ML, Suh HS and Lee SC. CD45 isoform expression in microglia and inflammatory cells in HIV-1 encephalitis. Brain Pathol 2006; 16: 256-265.
24. Stein VM, Baumgartner W, Schroder S, Zurbriggen A, Vandevelde M and Tipold A. Differential expression of CD45 on canine microglial cells. J Vet Med A Physiol Pathol Clin Med 2007; 54: 314-320.
25. Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G, Griffiths E, Krawczyk C, Richardson CD, Aitken K, Iscove N, Koretzky G, Johnson P, Liu P, Rothstein DM and Penninger JM. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 2001; 409: 349-354.
26. Irie-Sasaki J, Sasaki T and Penninger JM. CD45 regulated signaling pathways. Curr Top Med Chem 2003; 3: 783-796.
27. Streuli M, Hall LR, Saga Y, Schlossman SF and Saito H. Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens. J Exp Med 1987; 166: 1548-1566.
28. Akiyama H, Ikeda K, Katoh M, McGeer EG and McGeer PL. Expression of MRP14, 27E10, interferon-alpha and leukocyte common antigen by reactive microglia in postmortem human brain tissue. J Neuroimmunol 1994; 50: 195-201.
29. Cosenza MA, Zhao ML, Si Q and Lee SC. Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol 2002; 12: 442-455.
30. Johnston JB, Silva C, Gonzalez G, Holden J, Warren KG, Metz LM and Power C. Diminished adenosine A1 receptor expression on macro phages in brain and blood of patients with multiple sclerosis. Ann Neurol 2001; 49: 650-658.
31. Licastro F, Mallory M, Hansen LA and Masliah E. Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J Neuroimmunol 1998; 88: 105-110.
32. Masliah E, Mallory M, Hansen L, Alford M, Albright T, Terry R, Shapiro P, Sundsmo M and Saitoh T. Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease. Acta Neuropathol 1991; 83: 12-20.
33. Sedgwick JD, Ford AL, Foulcher E and Airriess R. Central nervous system microglial cell activation and proliferation follows direct interaction with tissue-infiltrating T cell blasts. J Immunol 1998; 160: 5320-5330.
34. Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford F and Mullan M. CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci 2000; 20: 7587-7594.
35. Tan J, Town T and Mullan M. CD45 inhibits CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK pathway. J Biol Chem 2000; 275: 37224-37231.
36. Suh HS, Kim MO and Lee SC. Inhibition of granulocyte-macrophage colony-stimulating factor signaling and microglial proliferation by anti-CD45RO: role of Hck tyrosine kinase and phosphatidylinositol 3-kinase/Akt. J Immunol 2005; 174: 2712-2719.
37. Kim MO, Suh HS, Si Q, Terman BI and Lee SC. Anti-CD45RO suppresses human immunodeficiency virus type 1 replication in microglia: role of Hck tyrosine kinase and implications for AIDS dementia. J Virol 2006; 80: 62-72.
38. Yang Y, Wu J and Lu Y. Mechanism of HIV-1-TAT induction of interleukin-1beta from human monocytes: Involvement of the phospholipase C/protein kinase C signaling cascade. J Med Virol 82: 735-746.
39. Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, Tan J and Fernandez F. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Brain Res Bull 2004; 64: 165-170.
40. Park IW, Wang JF and Groopman JE. HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood 2001; 97: 352-358.
41. Milani D, Mazzoni M, Zauli G, Mischiati C, Gibellini D, Giacca M and Capitani S. HIV-1 Tat induces tyrosine phosphorylation of p125FAK and its association with phosphoinositide 3-kinase in PC12 cells. Aids 1998; 12: 1275-1284.
42. Oshima T, Flores SC, Vaitaitis G, Coe LL, Joh T, Park JH, Zhu Y, Alexander B and Alexander JS. HIV-1 Tat increases endothelial solute permeability through tyrosine kinase and mitogenactivated protein kinase-dependent pathways. Aids 2000; 14: 475-482.
43. Avraham HK, Jiang S, Lee TH, Prakash O and Avraham S. HIV-1 Tat-mediated effects on focal adhesion assembly and permeability in brain microvascular endothelial cells. J Immunol 2004; 173: 6228-6233.
44. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR and Tan J. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 2004; 89: 337-343.
45. Rrapo E, Zhu Y, Tian J, Hou H, Smith A, Fernandez F, Tan J and Giunta B. Green Tea-EGCG reduces GFAP associated neuronal loss in HIV-1 Tat transgenic mice. Am J Transl Res 2009; 1: 72-79.
46. Jayadev S, Nesser NK, Hopkins S, Myers SJ, Case A, Lee RJ, Seaburg LA, Uo T, Murphy SP, Morrison RS and Garden GA. Transcription factor p53 influences microglial activation phenotype. Glia 59: 1402-1413.
47. Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR and Appel SH. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 2004; 55: 221-235.
48. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M and Hashizume Y. Distribution of major histocompatibility complex class IIpositive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 2003; 106: 518-526.
49. Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destee A, Tonnel AB, Lassalle P and Just N. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology 2005; 65: 1958-1960.
50. Nagatsu T and Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005; 11: 999-1016.
51. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S and Tarkowski A. Intrathecal release of pro-and antiinflammatory cytokines during stroke. Clin Exp Immunol 1997; 110: 492-499.
52. Glass JD and Wesselingh SL. Microglia in HIVassociated neurological diseases. Microsc Res Tech 2001; 54: 95-105.
53. Dheen ST, Kaur C and Ling EA. Microglial activation and its implications in the brain diseases. Curr Med Chem 2007; 14: 1189-1197.
54. Barish ME, Mansdorf NB and Raissdana SS. Gamma-interferon promotes differentiation of cultured cortical and hippocampal neurons. Dev Biol 1991; 144: 412-423.
55. Bernardino L, Agasse F, Silva B, Ferreira R, Grade S and Malva JO. Tumor necrosis factoralpha modulates survival, proliferation, and neuronal differentiation in neonatal subven tricular zone cell cultures. Stem Cells 2008; 26: 2361-2371.
56. Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, Brown RH, Jr. and Carroll MC. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A 2008; 105: 17913-17918.
57. Clarke RM, Lyons A, O'Connell F, Deighan BF, Barry CE, Anyakoha NG, Nicolaou A and Lynch MA. A pivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain. J Biol Chem 2008; 283: 1808-1817.
58. Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, Martino G and Schwartz M. Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci 2006; 31: 149-160.
59. Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM and Sisodia SS. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron 2008; 59: 568-580.
60. Salemi J, Obregon DF, Cobb A, Reed S, Sadic E, Jin J, Fernandez F, Tan J and Giunta B. Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD). Mol Neurodegener 6: 3.
61. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA and Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999; 286: 2352-2355.
62. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C and Brandt J. Nonsteroidal antiinflammatory drugs in Alzheimer's disease. Neurology 1995; 45: 51-55.
63. Garden GA, Budd SL, Tsai E, Hanson L, Kaul M, D'Emilia DM, Friedlander RM, Yuan J, Masliah E and Lipton SA. Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 2002; 22: 4015-4024.
64. Kaul M, Garden GA and Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410: 988-994.
65. Kaul M and Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U S A 1999; 96: 8212-8216.
66. Giovannetti A, Pierdominici M, Mazzetta F, Mazzone AM, Ricci G, Prozzo A, Pandolfi F, Paganelli R and Aiuti F. HIV type 1-induced inhibition of CD45 tyrosine phosphatase activity correlates with disease progression and apoptosis, but not with anti-CD3-induced T cell proliferation. AIDS Res Hum Retroviruses 2000; 16: 211-219.